International Faculty
Prof. Abdulrahman Jazieh
Director of Innovation and Research
Cincinnati Cancer Advisors
USA
Prof. Abdulrahman Jazieh
Director of Innovation and Research
Dr. Jazieh is a medical oncologist with a master’s degree in public health in health education and communication. Former Chairman of the International Affairs Committee of the American Society of Clinical Oncology (ASCO) and current chairman of the ASCO International Quality Steering Group. Dr. Jazieh has expertise in precision oncology, quality of care, and multidisciplinary care. He published more than 150 articles, books, and book chapters. Dr. Jazieh won multiple honors including Proclamation to the City of Cincinnati, naming a day in the City as Dr. Abdul Rahman Jazieh Day in 2006 and Special Recognition from NCCN as Global Partner in Cancer Care 2018. Merit Award Recipient from ASCO, “40 under 40” People to Watch at the University of Cincinnati Medical Center, and “Unsung Hero Award” by Cancer Family Care, Cincinnati.
Dr. Adam Brufsky
Professor of Medicine
UPMC Cancer Centers, University of Pittsburgh
USA
Dr. Adam Brufsky
Professor of Medicine
Adam M. Brufsky, MD, PhD, is Professor of Medicine at the University of Pittsburgh School of Medicine. Dr. Brufsky received an in Chemistry (Cum Laude) from Dartmouth College in Hanover, New Hampshire. He earned his MD and his PhD in Developmental Biology at the University of Connecticut School of Medicine in Farmington, CT. He was an Intern and Resident in Internal Medicine at Brigham and Women’s Hospital, Harvard Medical School, Boston, MA. He then completed a Fellowship in Medical Oncology and Bone Marrow Transplantation and the Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, where his appointments included Associate Physician and Instructor in Medicine at Dana Farber Cancer Institute and Harvard Medical School in Boston, MA. Dr. Brufsky is board certified in Internal Medicine and Medical Oncology by the American Board of Internal Medicine. He is an active member of the American Society of Clinical Oncology and the American Association for Cancer Research. He has authored or co-authored more than 300 abstracts and research articles in leading journals, including the New England Journal of Medicine, Journal of Clinical Investigation, Journal of Clinical Oncology, and Lancet Oncology. Dr. Brufsky is a Principal Investigator on a number of research grants funded by the National Institutes of Health, Susan G. Komen Foundation, and US Army Breast Cancer Research Program.
Dr. Ahmed Elkhanany
Assistant Professor
Dr. Ahmed Elkhanany is an oncologist in Houston, Texas and is affiliated with Baylor St. Luke's Medical Center. He received his medical degree from Alexandria University Faculty of Medicine and has been in practice between 11-20 years. Dr. Ahmed Elkhanany has expertise in treating breast cancer, small intestine/colorectal cancer, among other conditions
Dr. Alba Silverio Pons
Operational Research Nurse Lead
Vall d´Hebron Institute of Oncology
Spain
Dr. Alba Silverio Pons
Operational Research Nurse Lead
.
Dr. Alireza Mansouri
Assistant Professor, Department of Neurosurgery
The Pennsylvania State University
USA
Dr. Alireza Mansouri
Assistant Professor, Department of Neurosurgery
I am a Surgical Neuro-Oncologist at Penn State University with extensive post-graduate training in translational research and clinical trial design. Focusing on diffuse gliomas and brain metastases, my main research focus is on the interrogation of the brain tumor microenvironment to improve diagnosis/prediction of response and to better understand the effect of novel treatments. This involves a two-pronged approach: 1) implantation of microdialysis catheters in the brain for short-term local sampling of the tumor microenvironment subjected to novel drug therapy; and 2) liquid biopsy approaches for longitudinal analyses of the tumor microenvironment for development of minimally-invasive diagnostic/prognostic/predictive signatures.
Dr. Antonio Calles
Head, Lung Cancer Unit
Dr. Antonio Calles is Head, Lung Cancer Unit Head at Hospital Ruber Internacional, Madrid, Spain. He is also Faculty member for the Lung and other Thoracic Tumours faculty group at European Society for Medical Oncology (ESMO).
Dr. Antonio Vigano
Associate Professor, Department of Oncology
McGill University
Canada
Dr. Antonio Vigano
Associate Professor, Department of Oncology
Dr. Antonio Vigano, MD, MSc, is an associate professor in the departments of oncology and medicine at McGill University and director of McGill Nutrition and Performance Laboratory. He is also an attending physician at the Division of Supportive and Palliative Care Division at McGill University Health Center (MUHC) and the Director of Cancer Rehabilitation Program and Medical Cannabis Program in Oncology in Cedars Cancer Center, MUHC. Dr. Antonio is also a Co-lead biomedical axis at McGill Research Center for Cannabis in Canada.
Dr. Carmine De Angelis
Medical Oncologist
Carmine De Angelis, MD, PhD, is an Associate Professor in Medical Oncology at the University of Naples "Federico II" (Italy). He completed a postdoctoral fellowship at the Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas, under the supervision of Professor Kent Osborne and Professor Rachel Schiff. As a physician-scientist, his research focuses on elucidating the molecular mechanisms of response and resistance to endocrine therapy and anti-HER2 therapy in breast cancer. His research objective is to facilitate the translation of novel therapeutic strategies from the preclinical to the clinical setting.
Prof. Daniel Palmer
Professor and Honorary Consultant in Medical Oncology
University of Liverpool
United Kingdom
Prof. Daniel Palmer
Professor and Honorary Consultant in Medical Oncology
Professor Palmer took his current position of North West Cancer Research Chair in Medical Oncology at the University of Liverpool in 2011. His research interests relate to HPB cancers (liver, pancreas and biliary tract) and incorporate basic laboratory science, translational research and clinical trials. His laboratory research is currently investigating novel therapeutic approaches to the treatment of HPB cancer through stimulation of anti-tumour immune responses and targeting tumour micro-environment including the tumour microbiome, and developing and validating biomarkers for a stratified approach to treatment. He is a member of the UK NCRN Upper GI cancers clinical studies group, and the hepatobiliary and pancreatic sub-groups. He is Director of the Cancer Research UK/NIHR Liverpool Experimental Cancer Medicine Centre and has established a portfolio of early phase clinical trials and translational studies and he is Chief Investigator for the TACE-3 and RaTIO trials investigating immunotherapy combinations for patients with intermediate and advanced HCC respectively.
Dr. Denise Adams
Paediatric Haematologist-Oncologist and Director of the Comprehensive Vascular Anomalies Program
Children's Hospital of Philadelphia
USA
Dr. Denise Adams
Paediatric Haematologist-Oncologist and Director of the Comprehensive Vascular Anomalies Program
Denise Adams, MD is a pediatric hematologist-oncologist and Director of the Comprehensive Vascular Anomalies Program (CVAP) at Children’s Hospital of Philadelphia. She holds the Alan R. Cohen Endowed Chair in Pediatrics. Areas of Expertise: Vascular Anomalies Dr. Adams is a prominent pediatric hematologist-oncologist. She is the Director of the Comprehensive Vascular Anomalies Program (CVAP), a cutting-edge, multidisciplinary program that seeks breakthrough treatments and cures for children, adolescents and young adults with rare, life-threatening tumors and malformations of the vasculature, which includes the arteries, veins, capillaries, lymphatics and combined lesions.
Dr. Desiree Deandreis
Chief of the Nuclear Medicine Division
Désirée Deandreis is a nuclear medicine physician, chief of the nuclear medicine division at Gustave Roussy since 2023 and Associate Professor at University of Turin since 2016. Previously she served as chief of nuclear medicine division at AOU Città della Salute e della Scienza of Turin (Italy) from 2019 to 2022 and director of residency program of nuclear medicine at University of Turin from 2016 to 2022. From 2006 and 2016, she spent 10 years as nuclear medicine physician at Gustave Roussy with appraisal of the application of diagnostic and therapeutic nuclear medicine mainly in the field of endocrine tumors and prostate cancer. Furthermore, she spent 1 year at Memorial Sloan Kettering Cancer center in New York as visiting investigator.
Dr. Devan Moodley
Medical Oncologist
.
Dr. Francesco Massari
Senior Assistant Professor
Dr. Francesco Massari is currently responsible for the genitourinary oncology area at the Medical Oncology directed by Prof. Ardizzoni, of the IRCCS University Hospital of Bologna. Clinical and research activity with particular interest in neoplasms of the male and female urogenital system; in particular, the research activity is mainly aimed at the study of the mechanisms of resistance to the treatment of prostate and kidney cancer and the evaluation of the development of new molecules useful for the treatment of the aforementioned neoplasms. The scientific activity also sees Dr. Francesco personally involved, above all as principal investigator, in approximately 20 clinical trials (phase I-II-III studies, prospective, observational and retrospective studies) and clinical trials according to the rules of good clinical practice mainly concerning kidney, prostate and bladder cancer. He is an author of around 400 publications in international journals.
Dr. Fred Saad
Quebec Cancer Consortium's project leader
Centre hospitalier de l'Université de Montréal
Canada
Dr. Fred Saad
Quebec Cancer Consortium's project leader
Dr. Fred Saad is the Quebec Cancer Consortium’s project leader at the Centre hospitalier de l’Université de Montréal (CHUM). He is Professor and Chairman of Urology and Director of Genito-Urinary (G-U) Oncology at the CHUM. Dr. Saad holds the Raymond Garneau Chair in Prostate Cancer Research and is Director of clinical research and the molecular oncology research laboratory in prostate cancer. He has held several leadership positions such as President of the Canadian Urologic Association and Chair of the National Cancer Institute of Canada G-U Group and the Canadian Uro-Oncology Group. Over the last 20 years, Dr. Saad played a leadership role and is a co-author on many of the practice-changing clinical trials and publications in advanced prostate cancer.
Dr. Gerard Morton
Radiation Oncologist
Dr. Gerard Morton MD FRCPC is a Radiation Oncologist at the Sunnybrook Odette Cancer Centre, and Professor at the University of Toronto. His initial medical and clinical oncology training was in Ireland. He has a clinical and academic focus in genito-urinary malignancies, and has over 160 peer reviewed publications, mostly on prostate cancer. His particular interest is in brachytherapy, where he has led practice changing clinical trials of this modality. He sits on the RTOG/NRG Core GU Committee, is past chair of the ASTRO GU Committee and former Director of the American Brachytherapy Society. He is associate editor of Radiotherapy and Oncology, and Brachytherapy. He has been an invited speaker and visiting professor at many major centers throughout North America, Europe and Australia. He is a Fellow of the American Brachytherapy Society.
Dr. Giuseppe Fornarini
Medical Director
Dr. Fornarini Giuseppe is a medical director of San Martino Polyclinic Hospital - IRCCS, where he is also DMT Coordinator of "Urological Neoplasms" and has a Teaching role within the specialization school in Urology
Dr. Guillermo de Velasco
Academic Medical Oncologist
Dr. Guillermo de Velasco is a medical oncologist specializing in genitourinary tumors and melanoma. He earned his bachelor's and doctoral degrees from the Complutense University of Madrid and completed his residency at the 12 de Octubre Hospital. He has been awarded fellowships by ESMO and SEOM and conducted postdoctoral research at the University of Cambridge and the Dana-Farber/Harvard Cancer Center. An independent clinical researcher, he has published over 100 articles and leads clinical trials and translational studies on genitourinary tumors and melanoma at the 12 de Octubre University Hospital. Currently, he is an author of the ESMO clinical guidelines for renal cancer.
Prof. Haynes Van Der Merwe
Head: Unit for Gynaecologic Oncology
Western Cape Government
South Africa
Prof. Haynes Van Der Merwe
Head: Unit for Gynaecologic Oncology
Dr Haynes van der Merwe is a Gynaecologic Oncologist and is the current Head of the Gynaecologic Oncology Unit at Tygerberg Hospital and Stellenbosch University. After graduating with MBChB from Stellenbosch University in 1987 he did his Internship and another three years as Medical Officer in Paarl after which he worked as a General Practitioner in Paarl for almost 8 years. Following his training as registrar in the Department of Obstetrics and Gynaecology at Tygerberg Hospital he was awarded FCOG by the COG and MMED (O & G) by Stellenbosch University in 2003. He took up a specialist position in the O & G Department at Tygerberg Hospital in 2003 and was registered as Sub-specialist Gynaecologic Oncologist in 2009. In 2016 he was appointed in his current position as the Head of the Gynaecologic Oncology Unit at Tygerberg Hospital. He is also a member of the International Gynaecologic Cancer Society (IGCS) and member of South African Society of Gynaecologic Oncologists (SASGO). He is a member of the HPV Board (current secretary) and serves as a director on the HPV Cervical Cancer Research Fund (HCCRF). Dr Van der Merwe is the immediate past-President of the South African Society of Obstetricians and Gynaecologists (SASOG) and as such is a member of the Executive Committee and Council.
Dr. Jack Bartram
Consultant Paediatric Haematologist
Great Ormond Street Hospital for Childrena
United Kingdom
Dr. Jack Bartram
Consultant Paediatric Haematologist
Dr Jack Bartram is a Consultant Paediatric Haematologist, and the Clinical Director of the Malignancy Diagnostic Service at Great Ormond Street Hospital for Children (GOSH), London, UK. His research interest involves using advanced molecular diagnostic techniques to predict outcomes and find targets for novel therapies for children with haematological malignancies, as well as the application of AI to these datasets. He is currently the Clinical Lead for Haematological Malignancy Genomics in the Genomic Laboratory Hub and has been responsible for the implementation of advanced genomics and whole genome sequencing into clinical practice. He the UK national lead in for Infant ALL where he has pioneered a heavily de-escalated treatment protocol and has recently published the latest Blood “How I treat Infant ALL” review.
Dr. Jeffrey Dome
Chief of the Division of Oncology
Children's National Medical Centre
USA
Dr. Jeffrey Dome
Chief of the Division of Oncology
Jeffrey Dome, MD, PhD, is chief of the Division of Oncology. Dr. Dome specializes in pediatric solid tumors, with an emphasis on Wilms Tumours and other pediatric kidney tumours. As chair of the Renal Tumour Committee for the Children’s Oncology Group (COG), Dr. Dome oversees clinical trials for Wilms tumours and other childhood kidney cancers in more than 200 children’s hospitals. He has authored more than 30 articles.
Dr. Joe Herman
Medical Director and Adjunct Professor
Histosonics, Northwell Health
USA
Dr. Joe Herman
Medical Director and Adjunct Professor
An internationally recognized cancer expert focusing on gastrointestinal malignancies, Joe co-founded and is currently the Chief Medical Officer (CMO) of the Canopy Cancer Collective Learning Health Network (LHN) and the Director for Clinical Research at the Northwell Health Cancer Institute. Joe provides team-based interdisciplinary patient care that is compassionate, innovative, and efficient. Having 20 years of experience in administration, clinical care, education, research, and leadership has prepared him well for this collective. Before joining Canopy Cancer Collective Joe directed clinical research at the University of Texas MD Anderson Cancer Center, then served as ad-interim Division Head of the Division of Radiation Oncology. Previously, Joe served as Director of Clinical Research for the Johns Hopkins University Department of Radiation Oncology where he initiated and co-directed the Pancreatic Multidisciplinary Clinic, while also partnering with administration and clinical teams to develop multidisciplinary clinics in other disease sites including prostate, head and neck, liver, and lung cancers. Joe has been a writing member for the National Comprehensive Cancer Network (NCCN), American College of Radiology (ACR), and American Joint Commission on Cancer (AJCC) guidelines committees. He is currently on the medical advisory board for the Pancreatic Cancer Action Network (PANCAN), part of the Cancer Accelerator Initiative for the Lustgarten Foundation, and member of the National Institutes of Health Pancreas Task Force. Joe lives in New York with his family, and spends his free time playing soccer with his kids.
Dr. John Glaholm
Consultant Clinical Oncologist
Dr John Glaholm is a Consultant Clinical Oncologist at The Royal Marsden Hospital in London UK and specialises in Radiotherapy treatment of lymphomas.He completed undergraduate training at Charing Cross Hospital, London, and postgraduate training in Clinical Oncology at The Royal Marsden Hospital. He subsequently became a Consultant Clinical Oncologist at The Queen Elizabeth Hospital, Birmingham, UK, where he primarily specialised in Head and Neck cancer, Colorectal cancer and Urological malignancies. He held the post of Honorary Senior Lecturer at the University of Birmingham, UK. He has authored/co-authored over 70 peer reviewed publications and has written several textbook chapters. In addition to his current clinical work at The Royal Marsden Hospital he is a Module leader, lecturer/tutor and examiner for the Institute of Cancer Research Master of Science degree course in oncology. He has a strong interest in clinical trial participation.
Dr. John Peter Perentesis
Chief of Oncology and Executive Co-director of the Cancer/Blood Institute
Cincinnati’s Children's Hospital
USA
Dr. John Peter Perentesis
Chief of Oncology and Executive Co-director of the Cancer/Blood Institute
Dr. John Perentesis is a leader in the development of novel therapies and technologies for treating high-risk and relapsed pediatric and young adult cancers. He has served as Chief of Oncology and Executive Co-director of the Cancer/Blood Institute at Cincinnati Children's since 2011, and as Director of Cancer Programs since 2002. Dr. Perentesis has been instrumental in advancing research and therapy for acute myeloid leukemia (AML), leading efforts that contributed to the FDA approval of Vyxeos (CPX-351) for pediatric AML. In the Children's Oncology Group (COG), he has served on the Executive Committee and as chair of the AML relapse committee. His work includes leading new anticancer drug discovery, developing advanced proton therapy approaches, and conducting the first FLASH proton therapy clinical trial. Additionally, Dr. Perentesis plays a key role in developing national clinical trials through the National Cancer Institute and COG, focusing on new treatment regimens for pediatric and young adult cancers.
Dr. Julian Molina
Professor of Oncology
Consultant - Division of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, Minnesota Consultant - Division of Experimental Pathology and Laboratory Medicine, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota Consultant (Joint Appointment) - Department of Molecular Medicine, and Division of Experimental Pathology, Mayo Clinic, Rochester, Minnesota Master's Faculty Privileges in Clinical & Translational Sci. - Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic College of Medicine and Science Hospital Practice Chair - Division of Medical Oncology
Dr. Kostas Stamatopoulos
Hematologist, Research Director
Center for Research and Technology Hellas
Greece
Dr. Kostas Stamatopoulos
Hematologist, Research Director
Kostas Stamatopoulos is a hematologist, Research Director at the Institute of Applied Biosciences at CERTH, the Center for Research and Technology Hellas, Thessaloniki, Greece. He is the Scientific Coordinator of GRECRIN, the Greek Clinical Infrastructure Network; member of the Research and European Affairs Committes of the European Hematology association; Board member of ERIC, the European Research Initiative on chronic lymphocytic leukemia. Between 2018-2021 he coordinated the Hellenic Precision Medicine in Oncology. His research interests include: precision medicine in cancer; immunobiology of lymphoid malignancies with a particular focus on CLL; and, patient empowerment in care.
Prof. Lajos Pusztai
Professor of Medicine
Dr Pusztai is Professor of Medicine at Yale University, Scientific Co-Director of the Center for Breast Cancer at Yale Cancer Center and Co-Leader of the Yale Cancer Center Genomics Genetics and Epigenetics Program. He is also Chair of the Breast Cancer Research Committee of the Southwest Oncology Group (SWOG). Dr. Pusztai received his medical degree from the Semmelweis University of Medicine in Budapest, and his D.Phil. degree from the University of Oxford in England. His research group has made important contributions to establish that estrogen receptor-positive and-negative breast cancers have fundamentally different molecular, clinical and epidemiological characteristics. He has been a pioneer in evaluating gene expression profiling as a diagnostic technology to predict chemotherapy and endocrine therapy sensitivity and have shown that different biological processes are involved in determining the prognosis and treatment response in different breast cancer subtypes. He also made important contributions to clarify the clinical value of preoperative (neoadjuvant) chemotherapy in different breast cancer subtypes and made important contributions to characterize the immune microenvironment of breast cancer. Dr Pusztai is also principal investigator of several clinical trials investigating new drugs, including immunotherapies for breast cancer. Over 20 years of academic career he has mentored many graduate and postgraduate students who subsequently become academic thought leaders. He has published over 350 scientific manuscripts in high impact medical journals including the NEJM, JAMA, Journal of Clinical Oncology, Nature Biotechnology, PNAS, Lancet Oncology and JNCI. He is among the top 1% most highly cited investigators in clinical medicine according to a 2015 Thomson Reuters report. He is member of the Scientific Advisory Board of the Breast Cancer Research Foundation and a Susan Komen Scholar. The following is a link to his publications
Prof. M. Saiful Huq
Professor and Director, Medical Physics, Department of Radiation Oncology
University of Pittsburgh Medical Center Cancer Centers
USA
Prof. M. Saiful Huq
Professor and Director, Medical Physics, Department of Radiation Oncology
M. Saiful Huq, PhD, is Director of Medical Physics at UPMC Hillman Cancer Center and a Professor at the University of Pittsburgh School of Medicine. He manages operations across 24 cancer centers in Pittsburgh and is certified by the American Board of Radiology. Dr. Huq has authored 185 peer-reviewed publications, delivered 240 invited talks worldwide, and served as an examiner for ABR, ABMP, and IMPCB. A Fellow of American Association of Physicists in Medicine (AAPM) and the Institute of Physics, he held key leadership roles, including AAPM President and Board Chair. He has received numerous awards, including AAPM’s Coolidge Gold Medal award, Lifetime achievement award from Upstate New York chapter of AAPM, and authored IAEA’s radiotherapy guidelines.
Dr. Mohamad Shelan
Senior Radiation Oncology Consultant
PD Dr. Shelan holds the position of Senior Radiation Oncology Consultant at the University of Bern, Switzerland, and boasts nearly 13 years of comprehensive experience within the field of radiation therapy. This experience has been acquired through roles held at esteemed university hospitals in Germany and Switzerland, renowned for their unwavering dedication to evidence-based, high-caliber oncological care. Beyond his clinical responsibilities, PD Dr. Shelan has made substantial contributions as an educator. Since 2017, he has served as a dedicated tutor for medical students at the University Hospital Bern. Furthermore, PD Dr. Shelan has actively engaged as a principle investigator in a range of clinical and translational research endeavors. This involvement has spanned retrospective and prospective studies conducted at both national and international levels. He has also demonstrated his commitment to advancing the field as an author of numerous peer-reviewed publications and has lent his expertise as a reviewer and editor for esteemed international journals. PD Dr. Shelan possesses a specialist interest in Genitourinary, Lung, and Head & Neck cancers
Dr. Neil Rabin
Consultant Haematologist
University College London Hospitals NHS Foundation Trust
United Kingdom
Dr. Neil Rabin
Consultant Haematologist
Dr Neil Rabin is a Consultant Haematologist at University College London Hospitals NHS Foundation Trust. He has been serving in this role since his appointment in 2010. Dr Rabin specialises in haematology with a particular focus on myeloma. His areas of expertise include clinical trials evaluating new treatments for myeloma both at diagnosis and at relapse. Dr Rabin is deeply involved in the advancement of medical research and is committed to improving patient outcomes through innovative treatment options. He is passionate about exploring new therapies and their potential benefits for patients suffering from myeloma. In his role at University College Hospital, Dr Rabin is responsible for overseeing clinical trials, managing patient care, and collaborating with a multidisciplinary team to ensure comprehensive treatment plans. His dedication to his field is evident in his continuous efforts to stay at the forefront of haematological research and treatment.
Dr. Pablo Moroto
Medical Oncologist
renowned medical oncology specialist who has developed his professional career with a focus on clinical research. An expert in urological cancers and tumours, testicular germ cell tumours, metastatic prostate cancer, advanced bladder carcinoma, and metastatic renal cell carcinoma, among others Head of the Urologic Oncology Unit at the Hospital de la Santa Creu i Sant Pau in Barcelona. Associate Professor of Medicine at the Autonomous University of Barcelona. Professor of the School of Nursing at the Autonomous University of Barcelona. Graduate of Medicine and Surgery from the University of Santiago de Compostela. Graduated Cum Laude as a Doctor of Medicine and Surgery from the Autonomous University of Barcelona in 1998. Fellow of the Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, USA. American Board Certified since June 1999. Active member of the SEOM (Spanish Society of Medical Oncology). Active member of the EORTC (European Organisation for Research and Treatment of Cancer). Active member of the ASCO (American Society of Clinical Oncology). His work involves multiple congresses and various publications. He has published over 100 peer-reviewed articles, a notable example of which is the co-authoring of Clinical Guides and Consensus Documents.
Dr. Paul Kelly
Consultant Radiation Oncologist and Medical Director
Bon Secours Radiotherapy Cork in partnership with UPMC Hillman Cancer Centre
Ireland
Dr. Paul Kelly
Consultant Radiation Oncologist and Medical Director
Dr Paul Kelly is a Consultant Radiation Oncologist. He became a Fellow of the Faculty of Radiology at the Royal College of Surgeons in Ireland in 2008 and, thereafter, completed a 2-year Clinical Fellowship in Stereotactic Radiosurgery at Brigham and Women’s Hospital/Dana-Farber Cancer Institute in Boston, Massachusetts. Based in Cork since 2011 as a Consultant Radiation Oncologist he is active in clinical research and co-chairs the GU disease-specific subgroup (DSSG) of Cancer Trials Ireland. He is principal investigator on several prostate cancer and stereotactic radiotherapy clinical trials. His chief interests include prostate cancer, brain tumours, stereotactic radiotherapy. He took up a position as Medical Director of the new radiation oncology facility at the Bon Secours Radiotherapy Centre joint venture with University of Pittsburgh Medical Centre (UPMC) Hillman Cancer Centre in 2019.
Dr. Paul Sanghera
Consultant Clinical Oncologist
University Hospitals Birmingham
United Kingdom
Dr. Paul Sanghera
Consultant Clinical Oncologist
Dr. Paul is a Consultant Clinical Oncologist at University Hospitals Birmingham (UHB) with specialist interests in head and neck, neurological and skull base tumours. Prior to taking a consultant post in Birmingham, Paul undertook a fellowship at The University of Toronto. Paul re-joined as a consultant in Birmingham in 2008 where he led implementation of the cyberknife radiosurgery service. As subsequent radiotherapy lead at UHB his focus was on efficient access to IG-IMRT for all patients, and expansion of the stereotactic programme. Paul has been an investigator on several clinical trials, supported trial management groups and continues to serve on the national proton reference panel.
Prof. Philip McCarthy
Professor of Oncology and Internal Medicine
Roswell Park Comprehensive Cancer Center / SUNY
USA
Prof. Philip McCarthy
Professor of Oncology and Internal Medicine
Philip L. McCarthy, MD, is a Professor of Oncology & Internal Medicine, Director Emeritus of the Transplant & Cellular Therapy (TCT) Program and a member of the Department of Medicine at Roswell Park Comprehensive Cancer Center/SUNY at Buffalo. Dr. McCarthy’s research interests are devoted to developing novel intensive and reduced intensity allogeneic and autologous hematopoietic stem cell transplant (HSCT) and other cell therapy approaches for the treatment of hematologic disorders, leading to improved patient outcomes and decreased toxicity. He has focused on strategies to predict the development of severe Graft-versus-Host Disease and controlling its toxicity after allogeneic HSCT while preserving the beneficial Graft-versus-Tumor (GvT) effect. Another cell therapy interest is the utilization of Chimeric Antigen Receptor (CAR) T cell Therapy for hematologic malignancies in particular multiple myeloma (MM). He has a collaborative research program with Dr. Hemn Mohammadpour (Cell Stress Biology Program) and Dr. Jens Hillengass (MM Program) to investigate and modulate the immune microenvironment in cancer patients especially those with MM. He has over 25 years of experience treating patients with hematologic disorders, directing clinical and translational studies with a particular interest in multiple myeloma (MM). Philip L. McCarthy, MD, is a Professor of Oncology & Internal Medicine, Director Emeritus of the Transplant & Cellular Therapy (TCT) Program and a member of the Department of Medicine at Roswell Park Comprehensive Cancer Center/SUNY at Buffalo. Dr. McCarthy’s research interests are devoted to developing novel intensive and reduced intensity allogeneic and autologous hematopoietic stem cell transplant (HSCT) approaches for the treatment of hematologic disorders, leading to improved patient outcomes and decreased toxicity. He has over 25 years of experience treating patients with hematologic disorders, directing clinical and translational studies with a particular interest in multiple myeloma (MM). Dr. McCarthy has served as chair, or co-chair, of several clinical trials, including CALGB 100104, a phase III clinical trial evaluating lenalidomide maintenance after autologous HSCT for MM. This study demonstrated an improved progression-free and overall survival for MM patients receiving lenalidomide maintenance therapy after autologous HSCT. Dr. McCarthy facilitates the development of translational research projects that will lead to advances in the utilization of cellular therapy including immune effector cell treatment and allogeneic (allo) HCT as well as developing strategies for the early, successful treatment of hematologic malignancies.
Dr. Rajanee Bhana
Consultant Clinical Oncologist
University Hospitals of North Midlands
United Kingdom
Dr. Rajanee Bhana
Consultant Clinical Oncologist
Dr. Rajanee Bhana has 16 years Consultant Oncology experience in Gynaecological and Urological Malignancy in the United Kingdom. She works at the Cancer Centre at the University Hospitals of North Midlands NHS Trust. She did her undergraduate medical training in Johannesburg, South Africa at the University of the Witwatersrand and completed her Oncology Specialist training in the UK. She has been the Oncology Clinical Lead, Head of Service lead for the Royal College of Radiologist, Clinical Tutor and Educational Supervisor for Oncology Specialist Trainees and she is now the Director for Oncology, Haematology, Immunology and Palliative Care Directorate.
Prof. Robert Jones
Professor of Clinical Cancer Research
University of Glasgow
United Kingdom
Prof. Robert Jones
Professor of Clinical Cancer Research
Prof. Rob Jones is Professor of Clinical Cancer Research at the University of Glasgow and a Consultant medical oncologist at the Beatson West of Scotland Cancer Centre. His background includes a molecular biology PhD at the CRUK Beatson Institute and time spent working in Pharmaceutical Research and Development. His clinical practice is the medical management of cancers of the prostate and bladder. His research commitments include the management of a portfolio of phase I, II and III trials. He is director of the Glasgow Oncology Clinical Trials Unit, and head of the Cancer Clinical Trials Unit for Scotland collaboration (CaCTUS). He is a past chair of the UK NCRI Bladder and Renal Cancer Research Group and the Advanced Prostate Cancer subgroup.
Dr. Robin Norris
Professor of Pediatrics
Dr. Robin Norris is a Professor of Pediatrics at Cincinnati Children’s Hospital Medical Center, where she heads the clinical program in Hodgkin Lymphoma and serves as Co-Director of the Leukemia/Lymphoma Program. In Cincinnati, she is also the Director for Oncology Clinical Research, overseeing one of the nation's largest pediatric early-phase and frontline cancer clinical trials portfolios. Nationally, Dr. Norris is a member of the Children’s Oncology Group Hodgkin Lymphoma Steering Committee and is involved in planning the next National Cancer Institute Intergroup Trial for Advanced Stage Hodgkin Lymphoma.
Prof. Samreen Ahmed
Consultant Medical Oncologist
University Hospitals of Leicester, Leicester Royal Infirmary
United Kingdom
Prof. Samreen Ahmed
Consultant Medical Oncologist
Professor Ahmed has been a Consultant in Medical Oncology since 2006 and qualified in 1994 at the Royal Free Hospital School of Medicine London. She has a research degree (MD) through Nottingham University and received an Honorary Chair in 2016 from the University of Leicester. Professor Ahmed is the Training Programme Director for Medical Oncology in the East Midlands and Honorary secretary for the Association of cancer Physicians. She is a member of the BTOG Steering Committee and NCRI Lung Cancer Clinical Studies Group. NIHR award winner for clinical trials in 2015.
Prof. Sanjay Popat
Consultant Medical Oncologist
Professor Popat has both a private and an NHS practice at The Royal Marsden. He is a Consultant Medical Oncologist at The Royal Marsden, Professor of Thoracic Oncology at the Institute of Cancer Research, and is an internationally recognized expert in the treatment of lung cancer, mesothelioma and cancers of the thymus (thymoma and thymic carcinoma). Professor Popat qualified in 1994 from Guy’s and St Thomas’ Hospitals with triple distinction and was awarded a PhD in Molecular Genetics in 2002, undertaking a postdoctoral Clinician Scientist Fellowship and a HEFCE Clinical Senior Lectureship thereafter. He has been awarded nationally and internationally competitive prizes for his research, in addition to four research fellowships. His research interests include the complexities of genetic profiling in cancer, as well as developing novel drug treatments through clinical trials. He also holds several national and international roles. Nationally, Professor Popat Chairs the British Thoracic Oncology Group (BTOG) Steering Committee, is Co-Director for the NIHR London South Clinical Research Network Cancer Division, the NIHR Lung Cancer National Specialty Lead and is past Sub-group Chair of the NCRI Lung Group. Internationally, he sits on the Foundation Council of the European Thoracic Oncology Platform (ETOP) and is active in the European Society of Medical Oncology (ESMO) where he has co-authored European Clinical Practice Guidelines for Small Cell Lung Cancer, Non-Small Cell Lung Cancer, and Mesothelioma. His research collaborations with industry have led to licensing of several drugs globally, leading to implementation in International treatment guidelines and NHS funding approvals. Professor Popat is often an invited Clinical Expert to the National Institute for Health and Care Excellence (NICE) and sits on several committees overseeing the safety and governance for ongoing UK and international clinical trials. Sanjay is a strong advocate for patient education and support and is clinical advisor to several patient-facing cancer charities.
Dr. Shahzada Khurram Ahmed
Consultant ENT and Skull Base Surgeon
University Hospitals Birmingham NHS Foundation Trust
United Kingdom
Dr. Shahzada Khurram Ahmed
Consultant ENT and Skull Base Surgeon
Dr. Shahzada Ahmed, Consultant ENT and Skull Base Surgeon, graduated from The University of Birmingham Medical School and obtained Higher Surgical Training in Hospitals in the West Midlands.He undertook advanced training in sinus and nasal surgery in South Africa, America, Germany and Switzerland, and then spent a year on an advanced rhinology fellowship with world renowned surgeons at Queens Medical Centre, Nottingham before he was appointed as Consultant ENT and Skull Base Surgeon at Birmingham’s Queen Elizabeth Hospital NHS Trust in 2010.
Dr. Shreerang Bhide
Consultant Clinical Oncologist
Dr Shreerang Bhide is a Consultant Clinical Oncologist, Head of HN Unit and Honorary Reader at The Royal Marsden Hospital and The Institute of cancer Research in London and Sutton. He specialises in the treatment of patients with Head and Neck using advanced radiotherapy techniques such as IMRT and IGRT. He leads the research programme investigating the role of circulating HPV DNA in HPV related cancers at ICR/RMH. On the technical side he leads the MR-Linac implementation for head and neck cancers at the Royal Marsden Hospital. His other research interests include investigating the molecular determinants of response to chemotherapy and radiotherapy, in tumours and normal tissues in head and neck cancer.
Prof. Sibylle Loibl
Chair of the German Breast Group and the Chief Executive Officer
GBG Forschungs GmbH
Germany
Prof. Sibylle Loibl
Chair of the German Breast Group and the Chief Executive Officer
Prof. Dr. Sibylle Loibl is Chair of the German Breast Group and the Chief Executive Officer of the GBG Forschungs GmbH; Neu-Isenburg/Frankfurt/M, Germany Prof. Dr. Loibl is a professor of obstetrics and gynecology at the Goethe University of Frankfurt. She gained a doctorate at the Ruprecht Karl University of Heidelberg and trained as a consultant in gynaecology and obstetrics. She devotes most of her time to clinical research within the German Breast Group. Prof. Loibl has gained international renommée for her research in neoadjuvant breast cancer, breast cancer during pregnancy and young women. In addition, Prof. Loibl has been involved in conducting and managing a significant number of national and international, practice changing clinical trials.
Prof. Siow Ming Lee
Professor of Medical Oncology
University College London Hospitals NHS Foundation Trust
United Kingdom
Prof. Siow Ming Lee
Professor of Medical Oncology
Professor Siow Ming Lee (Prof. Lee) is Professor of Medical Oncology at University College London (UCL), and Consultant Medical Oncologist at University College London Hospitals (UCLH). He graduated from St. Mary’s Hospital Medical School, University of London in 1982, trained in internal medicine at the London teaching hospitals of St Mary’s, St Bartholomew’s and King’s College hospitals before completing his medical oncology fellowship training at Guy’s Hospital in London and Christie Hospital in Manchester.
Dr. Stephanie Graff
Director Breast Oncology
As Director of breast oncology at the Brown University Health Cancer Institute, Stephanie Graff, MD, shares her commitment to breast cancer research and advocacy with her patients and colleagues. Before joining Brown, Dr. Graff held multiple positions at the Sarah Cannon Cancer Institute Network. She was national breast lead of clinical programs and associate director of the breast cancer research program in Nashville, and director of the clinical research program in Kansas City, Missouri. An active member of numerous boards of directors and professional committees, Dr. Graff has been involved with the American Cancer Society National Breast Cancer Roundtable, the Dr. Susan Love Research Foundation, the American Society of Clinical Oncology, and other prominent organizations. She has authored and co-authored many research papers and articles related to her areas of expertise and has been invited frequently to address and lecture on medical and scientific symposia and panels.
Prof. Sunil Badve
Professor in the Department of Pathology and Laboratory Medicine
Emory University School of Medicine
USA
Prof. Sunil Badve
Professor in the Department of Pathology and Laboratory Medicine
Prof. Sunil S. Badve, MD, FRCPath, is vice chair for Pathology Cancer Programs and a professor in the Department of Pathology and Laboratory Medicine at Emory University School of Medicine. A surgical pathologist and a translational researcher with expertise in breast cancer and thymic pathology, Dr. Badve has made seminal contributions to the role of tumor infiltrating lymphocytes in triple negative breast cancer and re-classification of thymic tumors. He is working through his research and collaborations to reimagine risk assessment in and capitalize on novel approaches to improve management of patients with breast cancer. Prior to joining Emory, Dr. Badve was on faculty at Indiana University in Indianapolis, Indiana and at Northwestern University, Chicago, Illnois.
Prof. Syed Hussain
Professor and Consultant in Medical Oncology
University of Sheffield
USA
Prof. Syed Hussain
Professor and Consultant in Medical Oncology
Professor Hussain graduated from Dow Medical College Karachi in 1994. He completed his general medical professional training in UK. He did his Doctorate in Oncology from University of Birmingham. He completed his medical oncology training in Birmingham, United Kingdom and received his certification and specialist registration in medical oncology. Professor Hussain is Professor and Honorary Consultant in Medical Oncology at the University of Sheffield and Sheffield Teaching Hospitals NHS Trust. His major areas of interest are management of urological cancers, clinical trials, early drug development and translational medicine. He has set up several clinical trials from early phase to late phase studies during his career. His work on organ preservation in bladder cancer moved all the way from an early phase I study (Hussain et al Annals of Oncology 2001) to phase II efficacy study (Hussain et al BJC 2004) that led to a Cancer Research UK funded study BC2001 trial that was reported in New England Journal of Medicine (James, Hussain, Hall et al April 2012). This study has now changed the standard of care for patients with muscle invasive bladder cancer opting for organ preservation treatment globally. He has tailored split dose cisplatin regimen that has led to expand the spectrum of patients receiving cisplatin-based chemotherapy in bladder cancer (Hussain et al BJC 2004). He is a principal investigator of several studies in urological cancers. He was chief investigator of a national randomised placebo-controlled phase II neo-adjuvant study (NEOBLADE) in muscle invasive bladder cancer. He has served as a chief investigator of various early phase clinical trials, and translational studies. He is a chief investigator of a first in human window of opportunity study (INVEST) investigating the role of intravesical/intratumoral atezolizumab in patients with bladder cancer undergoing curative cystectomy. This is sponsored by STH and funded by Roche. He is also chief investigator of an international window of opportunity trial SOGUG NEOWIN investigating the role of erdafitinib and cetrelimab in FGF mutant bladder cancer patients undergoing curative cystectomy. This is jointly led by Hussain (UK), with Andrea Necchi (Italy), Yohann Loriot (France) and Guillermo Velasco (Spain) as other co-chief investigators. This study is funded by Janssen. He has authored over 135 peer-reviewed publications including 4 book chapters in textbooks of oncology. His Google scholar H-index is 45 with over 13,100 citations (July 2024). He has published in high impact journals including New England Journal of Medicine, Lancet, Lancet Oncology, JAMA, JAMA Oncology, Journal of Clinical Oncology, European Urology, Annals of Oncology, Nature Communications, Clinical Cancer Research, British Journal of Cancer. He has been an invited speaker to number of national and international meetings and have delivered over 120 invited lectures. He has secured funding from cancer charities, national funding bodies and industries of over £20 million. Professor Hussain was the member of NCRI Bladder and Renal group and Chair of the NCRI- Advanced Bladder Cancer sub-group in his national role. Professor Hussain was the expert witness to NICE on successful technology appraisals of Atezolizumab (2017), Avelumab (2021) and Nivolumab in Bladder cancer (2022). He is working with NICE in technology appraisal of Erdafitinib ( 2024) and Enfortumab Vedotin ( 2025).
Dr. Tamsin Greenwell
Consultant Urological Surgeon
University College London Hospitals NHS Foundation Trust
United Kingdom
Dr. Tamsin Greenwell
Consultant Urological Surgeon
Dr. Tamsin Greenwell has been a consultant urological surgeon with a special interest in female, reconstructive and neuro-urology since 2002. Tamsin qualified in medicine from Manchester University in 1990, and did her urological training in Brighton, Guy's and Thomas's and UCLH and The Institute of Urology. She was awarded an MD for her research in laser tissue interactions in 2000. She has a significant interest in surgical education. She ran the UCL Diploma in Urology and MSc Urology courses and the Pan Thames Higher Surgical Training Teaching Programme from 2004 to 2012, she was the Urology Tutor at the Royal College of Surgeons of England from 2006 to 2011 and the BAUS Director of Education from 2010-2013. She was the Chair of the FNUU section of BAUS from 2016-2018 and is a member of the EAU ESGURS committee and the AUA GURS committee. She has published over 100 papers in topics related to her clinical interests of urinary tract fistula, urethral diverticulm, male and female urethral stricture disease, male and female urinary incontinence, and urinary tract reconstruction.
Dr. Tannaz Armaghany
Assistant Professor
Baylor college of medicine. Dan L Duncan Comprehensive cancer center
USA
Dr. Tannaz Armaghany
Assistant Professor
Dr Tannaz Armaghany is a GI medical oncologist and a clinical scientist at Dan Duncan comprehensive cancer center (DLDCCC) at Baylor College of medicine in Houston Texas, USA. She treats all types of GI cancers with special interest in hepatocellular carcinoma (HCC). She visits with patients in two clinic locations, and trains hematology and oncology fellows. She collaborates with basic and clinical scientist on clinical trials and is a part of a comprehensive team of experts dedicated to the treatment of HCC. Dr Armaghany is a primary investigator on CAR-T cell therapy for HCC (CATCH trial) and a co-investigator in multiple GI oncology cancers in her center.
Dr. Tareq Abuasab
Assistant Professor, Department of Medicine, Section of Hematology and Oncology
Baylor College of Medicine
USA
Dr. Tareq Abuasab
Assistant Professor, Department of Medicine, Section of Hematology and Oncology
Dr. Tareq Abuasab is a dedicated hematologist with a strong foundation in internal medicine and hematology. He earned his medical degree from the University of Jordan in 2011 and completed his internal medicine and hematology fellowship in Jerusalem, where he served as chief fellow. Following this, Dr. Abuasab pursued an intensive leukemia fellowship at the renowned MD Anderson Cancer Center, where he contributed to groundbreaking research in myeloid malignancies and received the American Society of Hematology’s Abstract Achievement Award twice. In August 2023, he joined the Section of Hematology and Oncology at Baylor College of Medicine in Houston, Texas, bringing his expertise in leukemia treatment and clinical research to this esteemed institution
Dr. Tomasz Kluszczynski
Strategy Consultant and Guest Lecturer
ACESO and Warsaw University of Technology
Poland
Dr. Tomasz Kluszczynski
Strategy Consultant and Guest Lecturer
Tomasz Kluszczynski is a healthcare, life sciences and HEOR expert and a visiting professor at Warsaw and Frankfurt Universities. He is the author of White Papers and articles on Patient Access, Value-Based Pricing, Value-Based Agreements, HTA and Plasma Derived Medicinal Products (PDMPs).Tomasz works across all sectors and with all stakeholders: Public (Regulators, Payers, Patient Organisations), Private (Biopharma, Industry Associations), and, at the intersection of both, through Public-Private partnerships. Kluszczynski has been, most recently, involved in transformative projects aimed at healthcare system’s sustainability, such as the EU Commission SOHO Regulation, EMA Task Force on Drug Shortages, and healthcare evolution towards a value-based system with Saudi Arabia MoH HTA Development and the UAE Ejadah Program.
Dr. Vanda Salutari
Medical Doctor at Gynecology Oncology Unit
Policlinico Agostino Gemelli of Rome
Italy